Department of Renal Medicine, Counties Manukau District Health Board, Auckland, New Zealand.
School of Medicine, Faculty of Medical and Health Sciences, University of Auckland, Auckland, New Zealand.
Perit Dial Int. 2020 Jul;40(4):405-418. doi: 10.1177/0896860819895177. Epub 2020 Feb 18.
There are a number of misconceptions around the identified early survival benefit of peritoneal dialysis (PD) relative to hemodialysis (HD), including that such benefits "even out in the end" since the relative risk of death over time eventually encompasses 1.0 (or even an estimate that is unfavorable to PD); that the early benefit is, in fact, most likely due to unmeasured confounding; and such benefits are only due to the influence of central venous catheters and "crash starters" in the HD group. In fact, the early survival benefit results in a substantial gain of patient life years in PD cohorts relative to HD ones, even if it the benefit appears to "even out in the end," is relatively insensitive to unmeasured confounding, and persists even when the effects of central venous catheters are accounted for. In this review, the calculations and arguments are made to support these tenets. Survival on dialysis is still one of the most important considerations for all stakeholders in the end-stage kidney disease community, including patients who rank it among their top priorities. Shared decision-making is a fundamental patient right and requires both balanced information and an iterative mechanism for a consensual decision based on shared understanding and purpose. A cornerstone of this process should be an explicit discussion of the early survival benefit of PD relative to HD.
围绕腹膜透析 (PD) 相对于血液透析 (HD) 的早期生存获益,存在一些误解,包括这种获益“最终会趋于平衡”,因为随着时间的推移,死亡的相对风险最终会涵盖 1.0(甚至有估计对 PD 不利);早期获益实际上很可能归因于未测量的混杂因素;这种获益仅归因于 HD 组中中心静脉导管和“急救启动者”的影响。事实上,与 HD 队列相比,PD 队列的早期生存获益会使患者的生命年数显著增加,即使这种获益“最终会趋于平衡”,对未测量的混杂因素相对不敏感,并且即使考虑到中心静脉导管的影响,这种获益仍然存在。在这篇综述中,提出了计算和论证来支持这些原则。透析患者的生存率仍然是终末期肾病患者群体中所有利益相关者(包括将其列为首要考虑因素之一的患者)最关心的问题之一。共同决策是患者的一项基本权利,需要基于共享的理解和目标,提供平衡的信息和迭代机制来达成共识决策。这个过程的基石之一应该是明确讨论 PD 相对于 HD 的早期生存获益。